Event Details

Catalyst Biosciences at the 64th Annual Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis

July 18, 2018 12:00 PM EDT

Supporting Materials

Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor Ix Variant Cb2679d/Isu304: Pharmacokinetics and Safety 1.3 MB

Phase 2/3 Trial of Subcutaneously Administered Novel Fviia Variant Marzeptacog Alfa (Activated) In Hemophilia A or B with Inhibitors: Pharmacokinetics, Pharmacodynamics, Safety and Efficacy 2.7 MB

Home
Contact